Shares of Puma Biotechnology Inc (NASDAQ:PBYI) have received an average recommendation of “Hold” from the fifteen research firms that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $91.25.
A number of brokerages have commented on PBYI. Goldman Sachs Group began coverage on Puma Biotechnology in a report on Monday, September 17th. They set a “sell” rating and a $42.00 price objective for the company. Cowen reissued a “hold” rating and set a $80.00 price objective on shares of Puma Biotechnology in a report on Friday, August 10th. BidaskClub lowered Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Saturday, June 30th. ValuEngine raised Puma Biotechnology from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 2nd. Finally, Guggenheim began coverage on Puma Biotechnology in a report on Monday, September 17th. They set a “buy” rating for the company.
PBYI stock traded down $0.13 during trading on Friday, reaching $43.44. 8,039 shares of the stock were exchanged, compared to its average volume of 594,570. Puma Biotechnology has a twelve month low of $40.25 and a twelve month high of $136.90. The company has a debt-to-equity ratio of 3.14, a quick ratio of 2.64 and a current ratio of 2.68. The company has a market cap of $1.67 billion, a P/E ratio of -5.73 and a beta of -0.23.
Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.09. Puma Biotechnology had a negative return on equity of 367.92% and a negative net margin of 146.27%. The business had revenue of $50.80 million for the quarter, compared to the consensus estimate of $45.67 million. During the same period in the prior year, the business earned ($1.38) EPS. Equities analysts predict that Puma Biotechnology will post -3.84 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in PBYI. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Puma Biotechnology by 307.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,547 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 1,167 shares in the last quarter. NumerixS Investment Technologies Inc bought a new position in shares of Puma Biotechnology in the second quarter valued at approximately $141,000. Boston Advisors LLC bought a new position in shares of Puma Biotechnology in the second quarter valued at approximately $262,000. Royal Bank of Canada grew its holdings in shares of Puma Biotechnology by 271.3% in the first quarter. Royal Bank of Canada now owns 4,021 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 2,938 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Puma Biotechnology in the second quarter valued at approximately $289,000. 92.34% of the stock is owned by institutional investors.
About Puma Biotechnology
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).
Further Reading: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.